World Health Organization Issues Alert Over Critical Scarcity of Weight-Loss Injections
Fewer than 10% of people eligible to benefit from GLP-1 drugs including Wegovy can access them, states the WHO as it publishes its first recommendations on the medications.
Considering over a billion individuals worldwide now classified as obese, it is advocating for increased and just availability to these injectable treatments.
Per estimates, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The new guidelines affirms that excess weight is a long-term condition that can be addressed with comprehensive and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major barriers to universal access to the jabs that can help people shift considerable body mass, explains the body.
Weight-Loss Drug Supply Crisis
Even in the present most optimistic case, the manufacturing of these medications could only cover approximately 100 million people – fewer than 10% of eligible patients, according to the WHO.
The recommendation urges countries and companies to widen availability, by approaches like licensing agreements.
The intellectual property rights on a key compound – the core component of the drug Wegovy – is set to lapse in several nations in 2026.
How Weight-Loss Injections Work
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so individuals eat less.
People commonly see weight reduction after several weeks of commencing the once-weekly jabs.
Research suggests users may see weight return within a year of stopping the medication, as their normal appetite resume.
To be overweight or obese increases your risk for developing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns people in all nations and was associated with millions of deaths worldwide in 2024, as per the health agency.
